Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
As CCO of Grünenthal, Janneke van der Kamp’s focus will be to further strengthen Grünenthal’s commercial activities and grow the company’s key brands, especially Qutenza® (8% capsaicin topical system) in the US. Janneke van der Kamp will also be responsible for the launch preparations of Grünenthal’s promising pipeline asset, resiniferatoxin (RTX), for treating patients with moderate to severe pain associated with knee osteoarthritis. An ongoing clinical Phase III programme across sites in Europe, the US, Latin America, South Africa, and Japan aims to enable marketing approval for the investigational medicine.
Janneke van der Kamp joins Grünenthal at an exciting point in the company’s transformation journey. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled. During this time, Grünenthal closed successful acquisitions with a total expected deal value of more than € 2 billion. Furthermore, the company expanded its geographical footprint, with its affiliate Averitas Pharma, Inc., commercialising Qutenza® (8% capsaicin topical system) in the US.
“I am thrilled to join Grünenthal at such an exciting time and work with colleagues across the world on our vision of a world free of pain,” says Janneke van der Kamp. “I am confident that together we will reach even more patients with our medicines and be optimally prepared for the launch of our late pipeline assets.”
Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles, including General Manager, Global Neurosciences Franchise Head, and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She has vast expertise in launching and growing key brands across several disease areas. Janneke van der Kamp is a studied chemist and holds an MBA from INSEAD.
Janneke van der Kamp succeeds Mark Fladrich, who will retire from Grünenthal after more than five years with the company. During this time, he transformed Grünenthal’s commercial organisation, contributing to the company’s strong profit growth throughout his tenure.
Janneke van der Kamp’s Bio can be read here: Leadership at Grünenthal | About us | Grünenthal (grunenthal.com)
Fabia KehrenHead of External Communications & Editorial managementTlf:+49 241 569-3269Fabia.email@example.com
Maren ThurowHead Global Commercial CommunicationGrünenthal GmbHMaren.Thurow@grunenthal.com
Information om Grünenthal Group
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.
More information: www.grunenthal.com
Click here for our Grünenthal Report 2021/2022
Follow us on:
LinkedIn: Grunenthal Group
Følg pressemeddelelser fra Grünenthal Group
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Grünenthal Group
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer22.11.2022 11:14:11 CET | Pressemeddelelse
AACHEN, Germany, 22 November 2022 –Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD. As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus w
Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 13:24:23 CEST | Pressemeddelelse
Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi
Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Pressemeddelelse
Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total cons
Grünenthal acquires testosterone treatment NebidoTM from Bayer14.7.2022 09:05:26 CEST | Press release
Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability. Aachen, Germany, 14 July 2022 –Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The bra
Grünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research7.7.2022 09:05:00 CEST | Press release
Aachen, Germany – 7 July 2022 – Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, Lichtenberg-Professor for Chemosensation at the RWTH Aachen University. The partners strive to develop a range of translational research tools and humanised preclinical models to enhance target validation. Under the terms of the agreement, Grünenthal will support the institutes led by Professor Lampert and Professor Spehr with approximately € 1 million of funding. Part of the funding allows for establishing two new post-doc positions. The exploratory efforts at the Uniklinik RWTH Aachen and RWTH Aachen University will, if successful, enable their subsequent integration into drug development activities at Grünenthal. Chronic pain is a considerable burden that impacts up to